Associations - Immunomodulator

No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	SV-102 Sensitive: B - Late Trials SV-102 Sensitive : B	SV-102 Sensitive: B - Late Trials SV-102 Sensitive : B
HLA-A*02	Solid Tumor	HLA-A*02	Solid Tumor	SQZ-AAC-HPV Sensitive: C2 – Inclusion Criteria SQZ-AAC-HPV Sensitive : C2	SQZ-AAC-HPV Sensitive: C2 – Inclusion Criteria SQZ-AAC-HPV Sensitive : C2
C1As	Multiple Myeloma	C1As	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
Chr t(14;20)	Multiple Myeloma	Chr t(14;20)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
SMAD4 deletion	Pancreatic Adenocarcinoma	SMAD4 deletion	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive : C3	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive : C3
CD8 positive	Melanoma	CD8 positive	Melanoma	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	Orca-T Sensitive: C4 – Case Studies Orca-T Sensitive : C4	Orca-T Sensitive: C4 – Case Studies Orca-T Sensitive : C4
KRAS G12D + STK11 mutation	Lung Cancer	KRAS G12D + STK11 mutation	Lung Cancer	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MAM-06.301 Sensitive: D – Preclinical MAM-06.301 Sensitive : D	MAM-06.301 Sensitive: D – Preclinical MAM-06.301 Sensitive : D

Immunomodulator

Immunomodulator

Associations(24)

Associations
(24)